Each day, doctors prescribe tens of millions of blood chemistry panels. These tests are performed using consumable titration reagents and optical spectroscopy; usually on high throughput automated machines. The consumable reagents are the main cost of the blood analysis, as well as the limiting factor to their portability and shelf-life.
The GAMMA project focuses on the natural spectral behaviour of the biochemical elements of the blood serum to determine their concentrations. Eliminating the need for reagents. Ergo, radically reducing the cost of analysis and making it more portable.
GAMMA is an open source spectrometer and a spectrum analysis service that uses only light, and no chemical reagents, to perform a blood serum chemistry panel at the point of care, providing healthcare-professionals with the mean to perform a blood chemistry analysis on-the-go for less than €2 per panel.
GAMMA is currently in the prototyping phase. Pre-clinical data should be published in 2020. Regulatory aprovable could be granted by 2022.
Few big players (Roche, Siemens, Abbott, Danaher...) control ~80% of the marketshare. When smaller companies (start-up) developing new medtechs start generating revenue, they are bought (M&A) by those big players. Despite the better logistics and distribution networks of the big players, the real incentive for those M&A is the cash-out for the shareholders of the start-up. This M&A habits prevent the emergence of new/small players in the IVD field; and it pushes towards the high price of healthcare.
The US and EU market represents 70% of the global IVD market shares but only 15% of the world population. Proof that IVD is both overpriced here, and under used there.